Suppr超能文献

万古霉素封管疗法的广泛和长期应用降低了革兰氏阴性菌引起的血液透析导管相关感染。

Generalized and Prolonged Use of Gentamicin-Lock Therapy Reduces Hemodialysis Catheter-Related Infections Due to Gram Negatives.

机构信息

Department of Hospital Epidemiology, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico.

Gastroenterology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico.

出版信息

Nephron. 2019;143(2):86-91. doi: 10.1159/000500549. Epub 2019 Jun 14.

Abstract

INTRODUCTION

The incidence of catheter-related bloodstream infections (CRBSI) ranges from 2.2 to 5.5 episodes per 1,000 catheter-days. Our aim was to evaluate the utility of a generalized and prolonged gentamicin-lock therapy in patients undergoing hemodialysis (HD) in a third-level hospital for the reduction in CRBSI.

METHODS

A prospective cohort analyzed before and after intervention. During intervention periods after each HD-session, the catheter lumens were locked with gentamicin/heparin for all patients compared to nonintervention periods were the same procedure was performed without gentamicin. Active surveillance was performed for HD CRBSI. Microbiologic assessment and epidemiological data were gathered. Continuous hand hygiene and water quality monitoring were performed.

RESULTS

The rates of CRBSI were reduced from 1.28 to 0.2 cases per 1,000 catheter-days when the lock therapy was employed (p = 0.001) The greatest reduction was for CRBSI caused by Pseudomonas aeruginosa were no cases were recorded during the intervention periods (p = 0.001). There was a significant reduction in the total number of isolates; Gram-negative bacterial species (-97.2%) and Gram-positive bacterial species (-61.5%) although only the former reached statistical significance (p = 0.0001). The difference in the absolute risk reduction was 20.56% (95% CI 14.46-26.66%), the calculated Number Needed to Treat was 5 (95% CI 3.8-6.9). No adverse effects were noted.

CONCLUSION

In the current study, gentamicin-lock therapy was associated with a significant reduction in CRBSI specially with P. aeruginosa and other Gram-negative bacteria. It proved to be safe and effective intervention when applied to the entire population of HD patients.

摘要

简介

导管相关血流感染(CRBSI)的发生率为每 1000 个导管日 2.2 至 5.5 例。我们的目的是评估在三级医院接受血液透析(HD)的患者中使用通用且延长的庆大霉素封管疗法降低 CRBSI 的效果。

方法

前瞻性队列分析,在干预前后进行。在每次 HD 治疗后,与非干预期相比,所有患者的导管腔均用庆大霉素/肝素锁定,而非干预期则不使用庆大霉素。对 HD-CRBSI 进行主动监测。收集微生物学评估和流行病学数据。持续进行手部卫生和水质监测。

结果

当使用锁疗法时,CRBSI 的发生率从每 1000 个导管日的 1.28 例降至 0.2 例(p = 0.001)。当使用锁疗法时,铜绿假单胞菌引起的 CRBSI 发生率降低最为显著,干预期间未记录到任何病例(p = 0.001)。总的分离株数量显著减少;革兰氏阴性菌(-97.2%)和革兰氏阳性菌(-61.5%),尽管只有前者达到统计学意义(p = 0.0001)。绝对风险降低差异为 20.56%(95%CI 14.46-26.66%),计算出的需要治疗的人数为 5(95%CI 3.8-6.9)。未观察到不良反应。

结论

在本研究中,庆大霉素封管疗法与 CRBSI 的显著降低相关,特别是铜绿假单胞菌和其他革兰氏阴性菌。当应用于所有 HD 患者时,它被证明是一种安全有效的干预措施。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验